Abbott Laboratories (ABT)

69.77
0.99 1.40
NYSE : Health Technology
Prev Close 70.76
Open 70.38
Day Low/High 69.16 / 70.86
52 Wk Low/High 54.84 / 74.92
Volume 3.53M
Avg Volume 6.85M
Exchange NYSE
Shares Outstanding 1.76B
Market Cap 127.39B
EPS 0.30
P/E Ratio 160.40
Div & Yield 1.12 (1.54%)

Latest News

Last Week's Portfolio Changes

We initiated a new position and downgraded another name last week.

Weekly Roundup

It was another volatile week in the U.S. equity markets.

Jim's Daily Rundown

Jim discusses our trim of Abbott Laboratories and more!

Trimming Abbott Labs and Textron

We need cash to give us optionality to buy a market pullback scenario, but we also need to let our winners run.

Shire, Abbott Labs May Pace Healthcare Stocks in 2019

Shire, Abbott Labs May Pace Healthcare Stocks in 2019

Healthcare has been the best performing sector of the market this year. Here are three buy-rated stocks to track now.

Abbott To Present At J.P. Morgan Healthcare Conference

Abbott To Present At J.P. Morgan Healthcare Conference

ABBOTT PARK, Ill., Dec.

Last Week's Portfolio Changes

We updated two price targets and downgraded the rating on another position.

Abbott, Glaxo, Casella and More: 'Mad Money' Lightning Round

Abbott, Glaxo, Casella and More: 'Mad Money' Lightning Round

Jim Cramer weighs in on Abbott, GlaxoSmithKline, Waste Management and more.

The Fed is In a Corner: Cramer's 'Mad Money' Recap (Thursday 12/7/18)

The Fed is In a Corner: Cramer's 'Mad Money' Recap (Thursday 12/7/18)

Investors are stressing about the economy and the Fed, which has little room to maneuver, Jim Cramer says.

Weekly Roundup

Once again, it was a volatile week for U.S. equities.

Here's What You Need to Know About the U.S.-China Trade Truce

Market sentiment has certainly improved from this weekend's events.

Weekly Roundup

The market responded favorably after Fed Chair Jerome Powell portrayed a more dovish stance on interest rates.

Video: Jim's Daily Rundown for Friday

Jim discusses Palo Alto Networks' earnings from Thursday night, why we remain bullish on Amazon and Salesforce.com, and much more!

Trade-War Stakes: Cramer's 'Mad Money' Recap (Thursday 11/29/18)

Trade-War Stakes: Cramer's 'Mad Money' Recap (Thursday 11/29/18)

Jim Cramer looks for stocks that have potential, especially if trade and tariff woes out of the G-20 meeting stir up volatility.

DowDuPont, AT&T, Home Depot: 'Mad Money' Lightning Round

DowDuPont, AT&T, Home Depot: 'Mad Money' Lightning Round

Jim Cramer takes a look at DowDuPont, AT&T, Home Depot, New York Mortgage Trust, Nio, Abbott Laboratories, Nielsen and more.

Portfolio Review: Focusing on the Stocks That Have Not Worked

We are in the process of reviewing the portfolio, addressing what positions need to be altered as we approach the end of the year.

Absolute Enters Into Support Agreement

Absolute Enters Into Support Agreement

VANCOUVER, Nov. 22, 2018 /CNW/ - Absolute® (TSX:ABT) (the " Company"), the end point visibility and control company, announced today that one of its largest shareholders has agreed to support the Company's nominees for directors being Salvatore Visca,...

Jim Cramer: 'Extremely Powerful Bear Market' Except for These Stocks

Jim Cramer: 'Extremely Powerful Bear Market' Except for These Stocks

Jim Cramer recommends that consumers use these stocks to buy the stocks that have been beaten down by the looming bear market.

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.

Weekly Roundup

Markets endured another volatile week.

New Approvals Allow Chronic Pain Sufferers To Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant

New Approvals Allow Chronic Pain Sufferers To Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant

- Neurostimulation of the dorsal root ganglion (DRG) can provide pain relief for patients battling chronic pain when previous treatment options were unsuccessful

October Was a 'Dream' for Investors, According to Marc Chaikin and Jim Cramer

October Was a 'Dream' for Investors, According to Marc Chaikin and Jim Cramer

Here's why October was a dream for investors.

Weekly Roundup

Markets had another volatile week as trade tensions crossed currents with a U.S. midterm election that was closer than many had predicted.

Reviewing Some Winners After the Election Results

We think defense stocks, among other sectors, can rally.

Weekly Roundup

Markets experienced more volatility this week.

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Stephen 'Sarge' Guilfoyle gives you a rundown of what's in his portfolio as the new month gets rolling.

Weekly Roundup

Markets were volatile again this week.

TheStreet Quant Rating: B (Buy)